1
|
Farghaly AM, Rizk OH, Darwish I, Hamza M, Altowyan MS, Barakat A, Teleb M. Design, Synthesis, Pharmacodynamic and In Silico Pharmacokinetic Evaluation of Some Novel Biginelli-Derived Pyrimidines and Fused Pyrimidines as Calcium Channel Blockers. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27072240. [PMID: 35408650 PMCID: PMC9000669 DOI: 10.3390/molecules27072240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/21/2022] [Accepted: 03/25/2022] [Indexed: 11/18/2022]
Abstract
Some new pyrimidine derivatives comprising arylsulfonylhydrazino, ethoxycarbonylhydrazino, thiocarbamoylhydrazino and substituted hydrazone and thiosemicarbazide functionalities were prepared from Biginelli-derived pyrimidine precursors. Heterocyclic ring systems such as pyrazole, pyrazolidinedione, thiazoline and thiazolidinone ring systems were also incorporated into the designed pyrimidine core. Furthermore, fused triazolopyrimidine and pyrimidotriazine ring systems were prepared. The synthesized compounds were evaluated for their calcium channel blocking activity as potential hypotensive agents. Compounds 2, 3a, 3b, 4, 11 and 13 showed the highest ex vivo calcium channel blocking activities compared with the reference drug nifedipine. Compounds 2 and 11 were selected for further biological evaluation. They revealed good hypotensive activities following intravenous administration in dogs. Furthermore, 2 and 11 displayed drug-like in silico ADME parameters. A ligand-based pharmacophore model was developed to provide adequate information about the binding mode of the newly synthesized active compounds 2, 3a, 3b, 4, 11 and 13. This may also serve as a reliable basis for designing new active pyrimidine-based calcium channel blockers.
Collapse
Affiliation(s)
- Ahmed M. Farghaly
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt;
- Correspondence: (A.M.F.); (A.B.); (M.T.)
| | - Ola H. Rizk
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt;
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Pharos University, Alexandria 21521, Egypt
| | - Inas Darwish
- Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria 21521, Egypt; (I.D.); (M.H.)
- Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Pharos University, Alexandria 21521, Egypt
| | - Manal Hamza
- Department of Clinical Pharmacology, Faculty of Medicine, Alexandria University, Alexandria 21521, Egypt; (I.D.); (M.H.)
| | - Mezna Saleh Altowyan
- Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia;
| | - Assem Barakat
- Department of Chemistry, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Department of Chemistry, Faculty of Science, Alexandria University, P.O. Box 426, Ibrahimia, Alexandria 21321, Egypt
- Correspondence: (A.M.F.); (A.B.); (M.T.)
| | - Mohamed Teleb
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt;
- Correspondence: (A.M.F.); (A.B.); (M.T.)
| |
Collapse
|
2
|
El-Wakil MH, Teleb M, Abu-Serie MM, Huang S, Zamponi GW, Fahmy H. Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide. Bioorg Chem 2021; 115:105262. [PMID: 34411980 DOI: 10.1016/j.bioorg.2021.105262] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 07/19/2021] [Accepted: 08/07/2021] [Indexed: 01/09/2023]
Abstract
T-type calcium channels are considered potential drug targets to combat cancer. Combining T-type calcium channel blockers with conventional chemotherapy drugs represents a promising strategy towards successful cancer treatment. From this perspective, we report in this study the design and synthesis of a novel series of N3-sustituted dihydropyrimidines (DHPMs) as anticancer adjuvants to cisplatin (Cis) and etoposide (Eto). Full spectral characterization of the new compounds was done using FT-IR, 1H NMR, 13C NMR, and HRMS. Structure elucidation was confirmed by 2D NMR 1H-H COSY, HSQC and NOESY experiments. Novel derivatives were tested for their Ca2+ channel blocking activity by employing the whole cell patch-clamp technique. Results demonstrated that most compounds were potential T-type calcium channel blockers with the triazole-based C12 and C13 being the most selective agents against CaV3.2 channel. Further electrophysiological studies demonstrated that C12 and C13 inhibited CaV3.2 currents with respective affinity of 2.26 and 1.27 µM, and induced 5 mV hyperpolarizing shifts in the half-inactivation potential. Subsequently, C12 and C13 were evaluated for their anticancer activities alone and in combination with Cis and Eto against A549 and MDA-MB 231 cancer cells. Interestingly, both compounds exhibited potential anticancer effects with IC50 values < 5 µM. Combination studies revealed that both compounds had synergistic effects (combination index CI < 1) on Cis and Eto through induction of apoptosis (p53 activation and up-regulation of BAX and p21 gene expression). Importantly, in silico physicochemical and ADMET assessment of both compounds revealed their potential drug-like properties with decreased risk of cardiac toxicity. Hence, C12 and C13 are promising anticancer adjuvants through inhibition of CaV3.2 T-type calcium channels, thereby serving as eminent leads for further modification.
Collapse
Affiliation(s)
- Marwa H El-Wakil
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Mohamed Teleb
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
| | - Marwa M Abu-Serie
- Department of Medical Biotechnology, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Egypt
| | - Sun Huang
- Department of Physiology & Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, University of Calgary, 3330 Hospital Drive NW, Calgary T2N 4N1, Canada
| | - Gerald W Zamponi
- Department of Physiology & Pharmacology, Hotchkiss Brain Institute, Alberta Children's Hospital Research Institute, University of Calgary, 3330 Hospital Drive NW, Calgary T2N 4N1, Canada
| | - Hesham Fahmy
- Department of Pharmaceutical Sciences, College of Pharmacy & Allied Health Sciences, South Dakota State University, Brookings, SD 57006, USA.
| |
Collapse
|
3
|
Fujii T, Sugimoto K, Noda T, Shimizu T, Matsuya Y, Sakai H. Inhibition of gastric H +,K +-ATPase by new dihydropyrazole derivative KYY-008. Biochem Biophys Res Commun 2021; 567:177-182. [PMID: 34166915 DOI: 10.1016/j.bbrc.2021.06.056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Accepted: 06/16/2021] [Indexed: 12/12/2022]
Abstract
The gastric proton pump (H+,K+-ATPase) responsible for the H+ secretion of gastric acid is an essential therapeutic target for acid-related diseases. H+,K+-ATPase belongs to a P2-type ATPase family. Here, we examined the effects of a newly synthesized dihydropyrazole derivative KYY-008 on the H+,K+-ATPase. KYY-008 concentration-dependently inhibited the enzyme activity of the ATPase in the membrane fractions prepared from isolated hog gastric mucosa and from human kidney HEK293 cells in which gastric H+,K+-ATPase is exogenously expressed. The IC50 values in these samples were 3.4 μM and 3.7 μM, respectively. In addition, KYY-008 significantly inhibited the H+,K+-ATPase-derived H+ uptake into the tightly sealed vesicles prepared from the hog gastric mucosa. In contrast, KYY-008 has no effect on the activities of other P2-type ATPases such as Na+,K+-ATPase and Ca2+-ATPase. KYY-008 did not change the ionic currents of voltage-dependent Ca2+ channels, that were potential targets for some dihydropyrazole derivatives. Together, we discovered a new dihydropyrazole derivative which acts as a selective inhibitor of gastric H+,K+-ATPase.
Collapse
Affiliation(s)
- Takuto Fujii
- Department of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan.
| | - Kenji Sugimoto
- Department of Synthetic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan
| | - Takafumi Noda
- Department of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan
| | - Takahiro Shimizu
- Department of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan
| | - Yuji Matsuya
- Department of Synthetic and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan
| | - Hideki Sakai
- Department of Pharmaceutical Physiology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, 930-0194, Japan
| |
Collapse
|
4
|
Huang Y, Wang J, Liu J, Shi D, Li X, Wang M, Lu T, Jiang B, Xia C, Lin H, Xu Y, Li J. Rapid Repurposing of Novel Combination Drugs for the Treatment of Heart Failure via a Computationally Guided Network Screening Approach. J Chem Inf Model 2021; 62:5223-5232. [PMID: 34151561 DOI: 10.1021/acs.jcim.1c00132] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Combination drugs, characterized by high efficacy and few side effects, have received extensive attention from pharmaceutical companies and researchers for the treatment of complex diseases such as heart failure (HF). Traditional combination drug discovery depends on large-scale high-throughput experimental approaches that are time-consuming and costly. Herein we developed a novel, rapid, and potentially universal computer-guided combination drug-network-screening approach based on a set of databases and web services that are easy for individuals to obtain and operate, and we discovered for the first time that the menthol-allethrin combination screened by this approach exhibited a significant synergistic cardioprotective effect in vitro. Further mechanistic studies indicated that allethrin and menthol could synergistically block calcium channels. Allethrin bound to the central cavity of the voltage-dependent L-type calcium channel subunit alpha-1S (CACNA1S) lead to a conformational change in an allosteric site of CACNA1S, thereby enhancing the binding of menthol to this allosteric site. In summary, we reported a potentially universal computational approach to combination drug screening that has been used to discover a new combination of menthol-allethrin against HF in vitro, providing a new synergistic mechanism and prospective agent for HF treatment.
Collapse
Affiliation(s)
- Yunyuan Huang
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Jiqun Wang
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Jiaqi Liu
- Key Laboratory of Pesticide & Chemical Biology (CCNU), Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, China
| | - Donglei Shi
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Xiaokang Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Manjiong Wang
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Taotao Lu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Bei Jiang
- College of Pharmacy and Chemistry, Dali University, 5 Xue Ren Road, Dali 671000, China
| | - Conglong Xia
- College of Pharmacy and Chemistry, Dali University, 5 Xue Ren Road, Dali 671000, China
| | - Houwen Lin
- Research Center for Marine Drugs, State Key Laboratory of Oncogenes and Related Genes, Department of Pharmacy, Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200127, China
| | - Yixiang Xu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| | - Jian Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China.,College of Pharmacy and Chemistry, Dali University, 5 Xue Ren Road, Dali 671000, China.,Clinical Medicine Scientific and Technical Innovation Center, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200092, China
| |
Collapse
|
5
|
Xue Y, Shen J, Liu G, Zhou Q, Zhou W, Luo S. Predictors, incidence, and prognostic significance of PR interval prolongation in patients with ST-segment elevation myocardial infarction. Coron Artery Dis 2020; 31:606-612. [DOI: 10.1097/mca.0000000000000908] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
6
|
Song D, Yu W, Ren Y, Zhu J, Wan C, Cai G, Guo J, Zhang W, Kong L. Discovery of bazedoxifene analogues targeting glycoprotein 130. Eur J Med Chem 2020; 199:112375. [DOI: 10.1016/j.ejmech.2020.112375] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 04/21/2020] [Accepted: 04/21/2020] [Indexed: 12/31/2022]
|
7
|
van Luijtelaar G, van Oijen G. Establishing Drug Effects on Electrocorticographic Activity in a Genetic Absence Epilepsy Model: Advances and Pitfalls. Front Pharmacol 2020; 11:395. [PMID: 32351383 PMCID: PMC7175742 DOI: 10.3389/fphar.2020.00395] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Accepted: 03/16/2020] [Indexed: 12/18/2022] Open
Abstract
The genetic rat models such as rats of the WAG/Rij strain and GAERS were developed as models for generalized genetic epilepsy and in particular for childhood absence epilepsy. These animal models were described in the eighties of the previous century and both models have, among others, face, construct and predictive validity. Both models were and are currently used as models to predict the action of antiepileptic medication and other experimental treatments, to elucidate neurobiological mechanisms of spike-wave discharges and epileptogenesis. Although the electroencephalagram (EEG)/electrocorticogram (ECoG) is imperative for establishing absence seizures and to quantify the for absence epilepsy typical spike-wave discharges, monitoring the animals behavior is equally necessary. Here an overview is given regarding the design of drug evaluation studies, which animals to use, classical and new EEG variables, the monitoring and quantification of the behavior of the rats, some pitfalls regarding the interpretation of the data, and some developments in EEG technology.
Collapse
Affiliation(s)
| | - Gerard van Oijen
- Donders Centre for Cognition, Radboud University, Nijmegen, Netherlands
| |
Collapse
|
8
|
Zhao Z, Ji M, Wang Q, He N, Li Y. Ca 2+ signaling modulation using cancer cell membrane coated chitosan nanoparticles to combat multidrug resistance of cancer. Carbohydr Polym 2020; 238:116073. [PMID: 32299562 DOI: 10.1016/j.carbpol.2020.116073] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2019] [Revised: 02/20/2020] [Accepted: 02/25/2020] [Indexed: 12/11/2022]
Abstract
Off-target drug delivery, together with multidrug resistance (MDR), are two keys obstacles that account for the disappointing outcome in clinical chemotherapy of cancer. To solve these dilemmas, Herein, we constructed cancer cell membrane (CCM) modified silica (CS) nanoparticles (CCM/CS) to co-deliver Ca2+ channel siRNA with doxorubicin (DOX) to construct a platform (CCM/CS/R-D) for the efficient therapy of cervical cancer. It was demonstrated that the optimal CCM/CS/R-D was spherical nanoparticles with size at 122.39 ± 4.69 nm and the surface charge of -27.76 ± 3.12 mV. In addition, the CCM/CS/R-D showed acid responsive drug release while high stability under physiological conditions with negligible hemolysis. The CCM/CS/R-D showed CCM mediated cellular uptake and efficient endosomal escape as well as siRNA transfection potential (comparable to that of PEI 25 K) on MDR cervical cancer cells (HeLa/DOX). Most importantly, the MDR of cancer cells was conquered through modulation of T-type Ca2+ (Cav) channels. It was observed that the Cav channel siRNA could negatively regulate the level of cytosolic Ca2+ concentration which triggered G0/G1 phase cell cycle arrest and elevated intracellular drug retention in HeLa/DOX cells without significantly affect the expression of P-glycolprotein (P-gp). The in vitro and in vivo experiments revealed that CCM/CS/R-D exerted greatly enhanced tumor targetability and therapeutic effect on HeLa/DOX, which was superior than CS/R-D or mono delivery system (CCM/CS/R or CCM/CS/D).
Collapse
Affiliation(s)
- Zhao Zhao
- Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Mei Ji
- Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
| | - Qianqing Wang
- Gynaecological Oncology, Xinxiang Central Hospital, Xinxiang 453000, China
| | - Nannan He
- Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Yue Li
- Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| |
Collapse
|
9
|
Teleb M, Rizk OH, Zhang FX, Fronczek FR, Zamponi GW, Fahmy H. Synthesis of some new C2 substituted dihydropyrimidines and their electrophysiological evaluation as L-/T-type calcium channel blockers. Bioorg Chem 2019; 88:102915. [PMID: 31005784 DOI: 10.1016/j.bioorg.2019.04.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Revised: 03/22/2019] [Accepted: 04/06/2019] [Indexed: 01/05/2023]
Abstract
Drugs targeting different calcium channel subtypes have strong therapeutic potential for future drug development for cardiovascular disorders, neuropsychiatric diseases and cancer. This study aims to design and synthesize a new series of C2 substituted dihydropyrimidines to mimic the structure features of third generation long acting dihydropyridine calcium channel blockers and dihydropyrimidines analogues. The target compounds have been evaluated as blockers for CaV1.2 and CaV3.2 utilizing the whole-cell patch clamp technique. Among the tested compounds, compound 7a showed moderate calcium channel blockade activity against CaV3.2. Moreover, the predicted physicochemical properties and pharmacokinetic profiles of the target compounds recommend that they can be considered as drug-like candidates. The results highlight some significant information for the future design of lead compounds as calcium channel blockers.
Collapse
Affiliation(s)
- Mohamed Teleb
- Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD 57007, USA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Ola H Rizk
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt; Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria 21311, Egypt
| | - Fang-Xiong Zhang
- Department of Physiology & Pharmacology, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary T2N 4N1, Canada
| | - Frank R Fronczek
- Department of Chemistry, College of Science, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Gerald W Zamponi
- Department of Physiology & Pharmacology, Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary T2N 4N1, Canada
| | - Hesham Fahmy
- Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University, Brookings, SD 57007, USA.
| |
Collapse
|
10
|
Teleb M, Rizk OH, Zhang FX, Fronczek FR, Zamponi GW, Fahmy H. Design, synthesis and pharmacological evaluation of some substituted dihydropyrimidines with L-/T-type calcium channel blocking activities. Bioorg Chem 2019; 83:354-366. [DOI: 10.1016/j.bioorg.2018.10.054] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 10/19/2018] [Accepted: 10/26/2018] [Indexed: 12/24/2022]
|
11
|
Yang HK, Son WS, Lim KS, Kim GH, Lim EJ, Gadhe CG, Lee JY, Jeong KS, Lim SM, Pae AN. Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain. J Enzyme Inhib Med Chem 2018; 33:1460-1471. [PMID: 30231778 PMCID: PMC6151954 DOI: 10.1080/14756366.2018.1513926] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
The treatment of neuropathic pain is one of the urgent unmet medical needs and T-type calcium channels are promising therapeutic targets for neuropathic pain. Several potent T-type channel inhibitors showed promising in vivo efficacy in neuropathic pain animal models and are being investigated in clinical trials. Herein we report development of novel pyrrolidine-based T-type calcium channel inhibitors by pharmacophore mapping and structural hybridisation followed by evaluation of their Cav3.1 and Cav3.2 channel inhibitory activities. Among potent inhibitors against both Cav3.1 and Cav3.2 channels, a promising compound 20n based on in vitro ADME properties displayed satisfactory plasma and brain exposure in rats according to in vivo pharmacokinetic studies. We further demonstrated that 20n effectively improved the symptoms of neuropathic pain in both SNL and STZ neuropathic pain animal models, suggesting modulation of T-type calcium channels can be a promising therapeutic strategy for the treatment of neuropathic pain.
Collapse
Affiliation(s)
- Hak Kyun Yang
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea
| | - Woo Seung Son
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea.,b Department of Chemistry , Yonsei University , Seoul , Republic of Korea
| | - Keon Seung Lim
- c 1ST Biotherapeutics Inc. , Seongnam , Gyeonggi-do , Republic of Korea
| | - Gun Hee Kim
- d Research Institute for Basic Sciences and Department of Chemistry, College of Sciences , Kyung Hee University , Seoul , Republic of Korea
| | - Eun Jeong Lim
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea
| | - Changdev G Gadhe
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea
| | - Jae Yeol Lee
- d Research Institute for Basic Sciences and Department of Chemistry, College of Sciences , Kyung Hee University , Seoul , Republic of Korea
| | - Kyu-Sung Jeong
- b Department of Chemistry , Yonsei University , Seoul , Republic of Korea
| | - Sang Min Lim
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea.,e Division of Bio-Medical Science and Technology , Korea University of Science and Technology , Daejon , Republic of Korea
| | - Ae Nim Pae
- a Convergence Research Center for Diagnosis, Treatment and Care System of Dementia , Korea Institute of Science and Technology , Seoul , Republic of Korea.,f Division of Bio-Medical Science & Technology, KIST School , Korea University of Science and Technology , Seoul , Republic of Korea
| |
Collapse
|
12
|
Sairaman A, Cardoso FC, Bispat A, Lewis RJ, Duggan PJ, Tuck KL. Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. Bioorg Med Chem 2018; 26:3046-3059. [DOI: 10.1016/j.bmc.2018.03.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Revised: 03/15/2018] [Accepted: 03/18/2018] [Indexed: 10/17/2022]
|
13
|
A domino Kornblum-DeLaMare/aza-Michael reaction of 3,6-dihydro-1,2-dioxines and application to the synthesis of the ceramide transport inhibitor (±)-HPA-12. Tetrahedron 2018. [DOI: 10.1016/j.tet.2017.11.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
14
|
Sahu M, Siddiqui N, Sharma V, Wakode S. 5,6-Dihydropyrimidine-1(2H)-carbothioamides: Synthesis, in vitro GABA-AT screening, anticonvulsant activity and molecular modelling study. Bioorg Chem 2018; 77:56-67. [PMID: 29331765 DOI: 10.1016/j.bioorg.2017.12.031] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 12/26/2017] [Accepted: 12/30/2017] [Indexed: 12/12/2022]
Abstract
Even after considerable advances in the field of epilepsy treatment, convulsions are inefficiently controlled by standard drug therapy. Herein, a series of pyrimidine-carbothioamide derivatives 4(a-t) was designed as anticonvulsant agents by doing some important structural modifications in well-known anticonvulsant drugs. Two classical animal models were used for the in vivo anticonvulsant screening, maximum electroshock seizure (MES) and subcutaneous pentylenetetrazole (scPTZ) models; followed by motor impairment study by rotarod method. The most active compound 4g effectively suppressed seizure effect in both the animal models with median doses of 15.6 mg/kg (MES ED50), 278.4 mg/kg (scPTZ ED50) and 534.4 mg/kg (TD50) with no sign of neurotoxicity. Furthermore, in vitro GABA-AT enzyme activity assay of 4g showed inhibitory potency (IC50) of 12.23 μM. The docking study also favored the animal studies.
Collapse
Affiliation(s)
- Meeta Sahu
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research (Formerly, Faculty of Pharmacy), Jamia Hamdard, New Delhi 110062, India
| | - Nadeem Siddiqui
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research (Formerly, Faculty of Pharmacy), Jamia Hamdard, New Delhi 110062, India.
| | - Vidushi Sharma
- Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Mehrauli-Badarpur Road, Pushp Vihar, Sector-3, New Delhi 110017, India
| | - Sharad Wakode
- Department of Pharmaceutical Chemistry, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Mehrauli-Badarpur Road, Pushp Vihar, Sector-3, New Delhi 110017, India
| |
Collapse
|
15
|
Bezençon O, Remeň L, Richard S, Roch C, Kessler M, Moon R, Mawet J, Ertel EA, Pfeifer T, Capeleto B. Discovery and evaluation of Ca v 3.1-selective T-type calcium channel blockers. Bioorg Med Chem Lett 2017; 27:5322-5325. [DOI: 10.1016/j.bmcl.2017.09.063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 09/27/2017] [Accepted: 09/29/2017] [Indexed: 11/30/2022]
|
16
|
Bezençon O, Remeň L, Richard S, Roch C, Kessler M, Ertel EA, Moon R, Mawet J, Pfeifer T, Capeleto B. Discovery and evaluation of Ca v 3.2-selective T-type calcium channel blockers. Bioorg Med Chem Lett 2017; 27:5326-5331. [DOI: 10.1016/j.bmcl.2017.09.062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 09/27/2017] [Accepted: 09/29/2017] [Indexed: 10/18/2022]
|
17
|
Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E. Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies. J Med Chem 2017; 60:9769-9789. [PMID: 29116786 DOI: 10.1021/acs.jmedchem.7b01236] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.
Collapse
Affiliation(s)
- Olivier Bezençon
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Bibia Heidmann
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Romain Siegrist
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Simon Stamm
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Sylvia Richard
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Davide Pozzi
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Olivier Corminboeuf
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Catherine Roch
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Melanie Kessler
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Eric A Ertel
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Isabelle Reymond
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Thomas Pfeifer
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Ruben de Kanter
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Michael Toeroek-Schafroth
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Luca G Moccia
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Jacques Mawet
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Richard Moon
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Markus Rey
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Bruno Capeleto
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| | - Elvire Fournier
- Chemistry, Biology and Pharmacology & Pre-clinical Development, Drug Discovery, Idorsia Pharmaceuticals Ltd. , Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland
| |
Collapse
|
18
|
Siegrist R, Pozzi D, Jacob G, Torrisi C, Colas K, Braibant B, Mawet J, Pfeifer T, de Kanter R, Roch C, Kessler M, Corminboeuf O, Bezençon O. Structure–Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. J Med Chem 2016; 59:10661-10675. [DOI: 10.1021/acs.jmedchem.6b01356] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Romain Siegrist
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Davide Pozzi
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Gaël Jacob
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Caterina Torrisi
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Kilian Colas
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Bertrand Braibant
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Jacques Mawet
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Thomas Pfeifer
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Ruben de Kanter
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Catherine Roch
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Melanie Kessler
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Olivier Corminboeuf
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| | - Olivier Bezençon
- Drug Discovery Chemistry,
Biology and Pharmacology, Actelion Pharmaceuticals Ltd., Gewerbestrasse
16, CH-4123 Allschwil, Switzerland
| |
Collapse
|